These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1220978)

  • 1. Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213.
    Rivera G; Avery T; Roberts DW
    Eur J Cancer (1965); 1975 Sep; 11(9):639-47. PubMed ID: 1220978
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia.
    Dombernowsky P; Nissen NI
    Eur J Cancer (1965); 1976 Mar; 12(3):181-8. PubMed ID: 939236
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cytosine arabinoside and VM-26 in induction treatment, failures and recurrences of childhood acute lymphoblastic leukemias].
    Navajas Gutiérrez A; Bezanilla Regato JL; Moya Calderón E; Piñán MA
    An Esp Pediatr; 1988 Oct; 29 Suppl 34():91-3. PubMed ID: 3214046
    [No Abstract]   [Full Text] [Related]  

  • 4. R17934-NSC238159: a new antitumor drug--II. Effect on mitotic cycle of L1210 leukemia cells in vivo and synergism with cytosine arabinoside (NSC63878).
    Atassi G; Schaus C; Tagnon HJ
    Eur J Cancer (1965); 1975 Sep; 11(9):609-14. PubMed ID: 1220976
    [No Abstract]   [Full Text] [Related]  

  • 5. [VM-26 and cytosine arabinoside in the treatment of acute refractory lymphoblastic leukemia in adults].
    Marín P; Grañena A; Carreras E; Sierra J; Olivé MT; Rozman C
    Sangre (Barc); 1984; 29(4-A):399-404. PubMed ID: 6594782
    [No Abstract]   [Full Text] [Related]  

  • 6. Sedimentation of DNA from L1210 cells after treatment with 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) or 1-beta-D-arabinofuranosylcytosine or both drugs.
    Roberts D; Hilliard S; Peck C
    Cancer Res; 1980 Nov; 40(11):4225-31. PubMed ID: 7471063
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias.
    Avery TL; Roberts D
    Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of VM-26 on the haematological responses of mice to L1210 leukaemia.
    Hacker M; Roberts D; Jackson CW
    Br J Cancer; 1980 Nov; 42(5):697-702. PubMed ID: 7459207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VM-26 and cytarabine combination chemotherapy in refractory or relapsed adult acute lymphoblastic leukemia.
    Carella AM; Santini G; Martinengo M; Giordano D; Nati S; Congiu A; Risso M; Vimercati R; Cerri R; Rossi E
    Haematologica; 1984; 69(6):747-51. PubMed ID: 6441752
    [No Abstract]   [Full Text] [Related]  

  • 10. Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents.
    Dorr RT; Alberts DS
    Invest New Drugs; 1983; 1(2):151-9. PubMed ID: 6678864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The epipodophyllotoxin derivatives VM26 and VP16: experimental and clinical aspects.
    Dombernowsky P; Hansen HH
    Eur J Haematol Suppl; 1988; 48():49-57. PubMed ID: 3073960
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of acute refractory lymphoblastic leukemia in the adult with VM-26 and ARA-C].
    Rafecas FJ; Sanz MA
    Sangre (Barc); 1984; 29(6):1052-3. PubMed ID: 6598235
    [No Abstract]   [Full Text] [Related]  

  • 13. VM26 therapy in children with drug-refractory lymphocytic leukemia.
    Rivera G; Dahl GV; Murphy SB; Bowman WP; Aur RJ; Avery TL; Simone JV
    Cancer Chemother Pharmacol; 1982; 7(2-3):169-72. PubMed ID: 7083458
    [No Abstract]   [Full Text] [Related]  

  • 14. The podophyllotoxin derivatives VP16-213 and VM26.
    Issell BF
    Cancer Chemother Pharmacol; 1982; 7(2-3):73-80. PubMed ID: 7044593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells.
    Vietti TJ; Valeriote FA; Kalish R; Coulter D
    Cancer Treat Rep; 1978 Sep; 62(9):1313-20. PubMed ID: 688275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide and teniposide in the treatment of acute leukemia.
    Björkholm M
    Med Oncol Tumor Pharmacother; 1990; 7(1):3-10. PubMed ID: 2187120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
    Radice PA; Bunn PA; Ihde DC
    Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
    [No Abstract]   [Full Text] [Related]  

  • 18. Teniposide (VM-26) and cytosine arabinoside as consolidation therapy in adult high-risk patients with acute lymphoblastic leukemia.
    Hoelzer D; Thiel E; Löffler H; Büchner T; Ganser A; Heil G; Kurrle E; Heimpel H; Koch P; Lipp T
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):92-7. PubMed ID: 3473688
    [No Abstract]   [Full Text] [Related]  

  • 19. Flux of teniposide (VM-26) across the plasma membrane of teniposide-resistant sublines of L1210 cells.
    Lee T; Roberts D
    Cancer Res; 1984 Jul; 44(7):2986-90. PubMed ID: 6722822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of L1210 leukemia to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea plus 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside).
    Roberts D; Peck C; Hilliard S; Karas JG
    Cancer Res; 1981 Oct; 41(10):3891-5. PubMed ID: 7284998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.